Current Cancer Clinical Trials
at DeKalb Medical
DeKalb Medical is currently participating in the following cancer clinical trials. If you see an open trial below that you're interested in, please contact the DeKalb Medical Clinical Trials staff at 404.501.5701 or email us at clinicaltrials@dekalbmedical.org.
BREAST CANCER
ACOSOG Z11102:
This trial is looking at the impact of lumpectomy, instead of mastectomy, on surgical and cosmetic outcomes in patients with multiple tumors in the ipsilateral breast.
Study Abstract: http://www.cancer.gov/clinicaltrials/search/view?version=healthprofessional&cdrid=728605
Eligibility Criteria: https://www.ctsu.org/readfile.aspx?sectionid=32&fname=protocols/alliance/Z11102/Z11102_EC_OPENEnrollment_Form_112112.pdf
Schema: https://www.ctsu.org/readfile.aspx?sectionid=22&fname=protocols/alliance/Z11102/Z11102_Schema_Addendum1_112112.pdf
ECOG-E2108:
Randomized Phase III trial of the value of early local therapy for the intact primary tumor in patients with metastatic breast cancer
Study Abstract: http://www.cancer.gov/clinicaltrials/search/view?version=healthprofessional&cdrid=688097
Schema: https://www.ctsu.org/readfile.aspx?sectionid=22&fname=protocols/ecog/e2108/E2108_Schema_Addend2_071012.pdf
NSABP B-43:
A trial for breast patients with Her-2-positive DCIS. This is a trial looking at whether there is better disease free survival in patients who receive 2 doses of Herceptin along with their radiation therapy for DCIS.
Study Abstract: http://www.cancer.gov/clinicaltrials/search/view?version=healthprofessional&cdrid=615085
Eligibility Criteria: https://www.ctsu.org/readfile.aspx?sectionid=32&fname=protocols/nsabp/nsabp-b-43/B43_Eligibility_Checklist.pdf
Schema: https://www.ctsu.org/readfile.aspx?sectionid=22&fname=protocols/nsabp/nsabp-b-43/B-43_Schema.pdf
Physician Fact Sheet: https://www.ctsu.org/readfile.aspx?sectionid=31&fname=protocols/nsabp/nsabp-b-43/NSABP_B43_PFS_010612.pdf
NSABP B-47:
A trial for women who have a low percentage of Her-2 overexpression in their breast cancer. This trial is seeking to discover whether these women will benefit from the addition of Herceptin to their course of therapy.
Study Abstract: http://www.cancer.gov/clinicaltrials/search/view?version=healthprofessional&cdrid=692574
Eligibility Criteria: https://www.ctsu.org/readfile.aspx?sectionid=32&fname=protocols/nsabp/nsabp-b-47/B47_EligibilityChecklist_121311.pdf
Schema: https://www.ctsu.org/readfile.aspx?sectionid=22&fname=protocols/nsabp/nsabp-b-47/B47_Schema_121311.pdf
Physician Fact Sheet: https://www.ctsu.org/readfile.aspx?sectionid=31&fname=protocols/nsabp/nsabp-b-47/NSABP_B47_PFS_121311.pdf
NSABP B-49:
A trial for women who have node positive or high risk node negative breast cancer. This trial is seeking to answer the question if anthracyclines can be removed from chemotherapy regimens while preserving equivalent disease outcomes.
Eligibility Criteria: https://www.ctsu.org/readfile.aspx?sectionid=32&fname=protocols/nsabp/nsabp-b-49/B49_EligibilityChecklist_030912.pdf
Schema: https://www.ctsu.org/readfile.aspx?sectionid=22&fname=protocols/nsabp/nsabp-b-49/B49_Schema_030912.pdf
Physician Fact Sheet: https://www.ctsu.org/readfile.aspx?sectionid=31&fname=protocols/nsabp/nsabp-b-49/NSABP_B49_PFS_030912.pdf
NSABP B-51:
A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chest Wall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy.
Eligibility Criteria: https://www.ctsu.org/readfile.aspx?sectionid=32&fname=protocols/nsabp/nsabp-b-51/B51_EligibilityCriteria_011113.pdf
Schema: https://www.ctsu.org/readfile.aspx?sectionid=22&fname=protocols/nsabp/nsabp-b-51/B51_Schema_011113.pdf
COLORECTAL CANCER
NSABP P-5:
For patients with resected Stage 0-III colon cancer, to determine the effect of rosuvastatin on 5-year occurrence rates of adenomatous polyps, metachronous colorectal cancer, or colorectal cancer recurrence.
Study Abstract: http://www.cancer.gov/clinicaltrials/search/view?version=healthprofessional&cdrid=658554
Eligibility Criteria: https://www.ctsu.org/readfile.aspx?sectionid=32&fname=protocols/nsabp/NSABP-P-5/P5_Eligibility_Worksheet_Amedn3_121212.pdf
Schema: https://www.ctsu.org/readfile.aspx?sectionid=22&fname=protocols/nsabp/NSABP-P-5/NSABP_P5_Schema_Amend3_110512.pdf
GENETICS
City of Hope Genetic Registry:
Patients and their families will be given the unique opportunity to take part in a confidential registry and biologic repository to help define the underlying predisposition to cancer. The study will help to answer questions about whether cancers may have a genetic or environmental cause (or both) and ultimately to learn more about susceptibility to cancer.
http://www.cityofhope.org/education/health-professional-education/cancer-genetics-career-development-program/research-requirements/Pages/research-projects.aspx
LUNG CANCER
ECOG E5508:
Randomized Phase III Study of Maintenance Therapy with Bevacizumab, Pemetrexed or Both Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Stage Non-Squamous Non-Small Cell Lung Cancer.
Abstract: http://www.cancer.gov/clinicaltrials/search/view?version=healthprofessional&cdrid=666482
Schema: https://www.ctsu.org/readfile.aspx?sectionid=22&fname=protocols/ecog/e5508/E5508_Schema_081210.pdf
Physician Fact Sheet: https://www.ctsu.org/readfile.aspx?sectionid=31&fname=protocols/ecog/e5508/E5508_PFS_042712.pdf
SWOG S0819:
A Randomized, Phase III Study Comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab with or without Concurrent Cetuximab in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC).
Abstract: http://www.cancer.gov/clinicaltrials/search/view?version=healthprofessional&cdrid=649817
Eligibility Criteria: https://www.ctsu.org/readfile.aspx?sectionid=32&fname=protocols/swog/s0819/S0819_EligibilityCriteria_041512.pdf
Physician Fact Sheet: https://www.ctsu.org/readfile.aspx?sectionid=22&fname=protocols/swog/s0819/S0819_Schema_071509.pdf
MULTIPLE MYELOMA
ECOG E3A06:
Randomized Phase III Trial of Lenalidomide Versus Observation Alone in Patients with Asymptomatic Smoldering Multiple Myeloma.
Study Abstract: http://www.cancer.gov/clinicaltrials/search/view?version=healthprofessional&cdrid=682012
Schema: https://www.ctsu.org/readfile.aspx?sectionid=22&fname=protocols/ecog/e3a06/E3A06_Schema_Addend5_022012.pdf
Physician Fact Sheet: https://www.ctsu.org/readfile.aspx?sectionid=31&fname=protocols/ecog/e3a06/E3A06_PFS_072512.pdf
PANCREATIC CANCER
SWOG S1115:
Randomized Phase II trial of AZD6244 Hydrogen Sulfate and MK-2206 vs. mFOLFOX in patients with metastatic pancreatic cancer after prior chemotherapy
Eligibility Criteria: https://www.ctsu.org/readfile.aspx?sectionid=32&fname=protocols/swog/s1115/S1115_EligibilityCriteria_Rev3_021513.pdf
Schema: https://www.ctsu.org/readfile.aspx?sectionid=22&fname=protocols/swog/s1115/S1115_Schema_Rev2_112612.pdf
PROMIS and NBRST Tumor Registry Study:
These studies incorporate MammaPrint, a 70-gene array, of the participants’ breast tumor. Results are made available to the patient and her physician for discussion of further treatment options. The study is looking at whether the MammaPrint results will have a bearing on treatment options.
PROMIS: http://www.agendia.com/pages/promis/522.php
NBRST: http://www.agendia.com/pages/nbrst/479.php